A novel enhanced delivery oligonucleotide (EDO) therapeutic demonstrates considerable potential in treating Duchenne muscular dystrophy.

**Dr Ashling Holland, Dr Sima Gunnew, Sam Ching, Rachel Johnson, Ca lum Irwin, Dr Sonia Bracaglidi, Dr Caroline Godfrey**

**PepGen**: BioEscalator, Innovation Building, Old Road Campus, Roosevelt Drive, Oxford, OX3 7FZ, United Kingdom

## INTRODUCTION

**WHAT ARE EDOs?**

Enhanced Delivery Oligos (EDO) are well-characterized therapeutic PMO oligonucleotides conjugated to proprietary delivery-enhancing peptides.

**THERAPEUTIC DELIVERY OLIGONUCLEOTIDE**

Optimal cellular uptake including in cardiac and skeletal tissues.

**PEPGEN’S LEAD EDO PROGRAMS ARE ENTERING THE CLINIC IN 2022**

<table>
<thead>
<tr>
<th>PROGRAM</th>
<th>TARGET</th>
<th>DISCOVERY</th>
<th>PRECLINICAL</th>
<th>CLINICAL</th>
<th>ESTIMATED PATIENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>DMD</td>
<td>Exon 51</td>
<td>2022</td>
<td>US ~10,000 with EDO, PepGen will address 30%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DMD</td>
<td>Other Exons</td>
<td>2022</td>
<td>US ~40,000</td>
<td></td>
<td></td>
</tr>
<tr>
<td>UNDISCLOSED</td>
<td>GENE X</td>
<td>2022</td>
<td>US ~40,000</td>
<td></td>
<td></td>
</tr>
<tr>
<td>UNDISCLOSED</td>
<td>GENE X</td>
<td>2022</td>
<td>US ~40,000</td>
<td></td>
<td></td>
</tr>
<tr>
<td>UNDISCLOSED</td>
<td>GENE X</td>
<td>2022</td>
<td>US ~40,000</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**PEPGEN’S EDO51 THERAPEUTIC SHOWS EXCEPTIONAL EFFICACY IN NHP**

**EDO51 IS SAFE AND TOLERABLE AT THERAPEUTICALLY RELEVANT DOSES**

**KEY FINDINGS**

- No mortality and no serious adverse events
- Therapeutic doses are well tolerated
- No impact on body weight
- No significant microscopic observations or organ changes
- Transient and reversible changes in urina and creatinine detected at doses above therapeutic dose range, no other significant changes were observed

**SUMMARY**

An exciting step-change in oligonucleotide delivery with the potential to transform the course of disease in DMD

Superior skeletal & cardiac muscle penetration and efficacy, allowing critical disease phenotypes to be addressed

A rapid path to the clinic: PepGen is on track to initiate first-in-human studies in 2022

Backed by world-leading investors, with an experienced team across Boston and Oxford offices